The lipid-lowering effects of Danhong and Huangqi injections: a meta-analysis of clinical controlled trials

Table 2 Meta-analysis of Huangqi injection with the changes in plasma lipid levels

Groups or subgroups	Studies (Subjects)	P _{Heterogeneity}	SMD (95% CI)	P _SMD
TG
All	6 (440)	< 0.001	−1.27 (− 2.53, 0.00)	0.05
Nephrotic syndrome	4 (274)	< 0.001	−1.49 (− 3.56, 0.58)	0.16
Low-dose (< 40 mL)	2 (196)	< 0.001	−3.49 (− 7.55, 0.57)	0.09
High-dose (≥ 40 mL)	4 (244)	< 0.001	−0.21 (−1.14, 0.73)	0.67
Short-duration (< 4 weeks)	2 (160)	< 0.001	−2.28 (−8.74, 4.19)	0.49
Long-duration (≥ 4 weeks)	4 (280)	< 0.01	−0.84 (−1.43, − 0.26)	< 0.01
TC
All	7 (542)	< 0.001	−1.13 (−2.09, −0.16)	0.02
Nephrotic syndrome	5 (376)	< 0.001	−1.41 (−2.88, 0.07)	0.06
Low-dose (< 40 mL)	3 (298)	< 0.001	−2.13 (−3.98, −0.29)	0.02
High-dose (≥ 40 mL)	4 (244)	< 0.001	−0.40 (−1.47, 0.67)	0.47
Short-duration (< 4 weeks)	2 (160)	< 0.001	−1.98 (−7.85, 3.89)	0.51
Long-duration (≥ 4 weeks)	5 (382)	0.03	−0.83 (−1.19, − 0.47)	< 0.001
LDL-C
All	3 (220)	0.72	−0.15 (− 0.41, 0.12)	0.28
HDL-C
All	3 (220)	< 0.05	0.28 (−0.22, 0.77)	0.27

SMD standardized mean difference, 95% CI 95% confidence interval, TG triglycerides, TC total cholesterol, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol

ISSN: 1476-511X